← Human Trials & Peer-Reviewed Studies
Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial.
Plain-language guide to PMID 36661855 (2023): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 303 women.
Key Facts
- PMID
- 36661855
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Pérez-Castrillón JL et al. (18 authors)
- DOI
- 10.1002/jbmr.4776
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Vitamin D plays a major role in bone health and probably also in multiple extraskeletal acute and chronic diseases.
By month 4, stable 25(OH)D levels were documented with both calcifediol and cholecalciferol (intention-to-treat population): 26.8 ± 8.5 ng/mL (Group A1) and 23.1 ± 5.4 ng/mL (Group B).
Who Took Part
The abstract describes 303 women taking part.
PubMed tags the participants as women only.
A total of 303 women were randomized and 298 evaluated.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.
The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
Some women received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
More than one site took part, so the women came from several places.
What Was Measured
By month 4, stable 25(OH)D levels were documented with both calcifediol and cholecalciferol (intention-to-treat population): 26.8 ± 8.5 ng/mL (Group A1) and 23.1 ± 5.4 ng/mL (Group B).
By month 12, 25(OH)D levels were 23.9 ± 8.0 ng/mL (Group A1) and 22.4 ± 5.5 ng/mL (Group B).
PubMed files the paper under topics including Calcifediol, Postmenopause, Vitamin D, Cholecalciferol, Vitamin D Deficiency and Dietary Supplements.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 303 women.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2023 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.